Mergers & Acquisitions
🇺🇸 FDA Page 4FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.
Showing 37–48 of 64 articles
Pfizer and Innovent's $10B Cancer Drug Deal: Key Insights
Pfizer and Innovent have entered a significant $10B deal focusing on cancer therapeutics. This article delves into the implications for the pharmaceutical landscape.
Trump's Pharma Deals Under Scrutiny: Insights and Implications
This article analyzes the recent scrutiny of Trump's pharmaceutical deals, focusing on their implications for business development teams and investors. Key insights and competitive impacts are discussed.
Trump's Drug-Pricing Deals: New Product Launches on the Horizon
As new pharmaceutical products are set to launch, Trump's drug-pricing deals face critical scrutiny. This article delves into the implications for business development teams and investors.
AstraZeneca's Breast Cancer Pill and ADAP Deal Insights
This article covers AstraZeneca's latest breast cancer pill developments and an ADAP deal in Florida, highlighting key implications for the pharmaceutical industry.
CordenPharma Expands Production Capacity with New CDMO Deal
CordenPharma's recent partnership with a peptide CDMO marks a significant expansion in GLP-1 production. This strategic move aims to bolster their manufacturing footprint in key markets.
Eli Lilly's New Gene Therapy and Strategic Deals: Insights for Investors
Eli Lilly is making headlines with a new gene therapy for cholesterol and several strategic deals. This article breaks down the implications for business development teams and investors.
Impact of COINS Act Expansion on China Biotech Licensing
The expansion of the COINS Act raises questions about its effects on China biotech licensing. This article explores the implications for BD teams and investors.
SK bioscience's $260M Deal for Varicella Vaccine Production in Colombia
SK bioscience has secured a $260M deal to manufacture varicella vaccines in Colombia, marking a significant investment in local production. This move has important implications for the pharmaceutical landscape in Latin America.
GOP Lawmaker Urges Action on China Biotech Deals
A GOP lawmaker has called for the Trump administration to take action against Chinese biotech investments. This article explores the potential impacts on the pharmaceutical sector.
Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss
This article delves into Merck-Kelun ADC's recent achievements in China and the implications of Takeda's significant antitrust loss, providing strategic insights for business development teams and investors.
Incyte's Strategic AI Partnerships: Implications for Pharma
Incyte has signed significant AI deals with Genesis Molecular AI and Edison Scientific, marking a pivotal moment for its innovation strategy. This article explores the implications for the pharmaceutical landscape.
Parabilis IPO Plans Following Regeneron Deal: What You Need to Know
Parabilis has announced its IPO plans just a day after the Regeneron deal, signaling a surge in listings. This article explores the implications for the pharmaceutical landscape.